Overview of glutamine metabolism in pulmonary arterial hypertension. Under pathological stress or upon activation of oncogenes, glutamine (Gln) is transported from extracellular to intracellular space by alanine-serine-cysteine transporter 2 (ASCT2) [also known as solute carrier family 1, member 5 (SLC1A5)]. Gln is then hydrolyzed to glutamate (GLU) and ammonia (NH3) driven by increased GLS expression in mitochondria. GLU is transformed into α-ketoglutaric acid (α-KG), which participates in the tricarboxylic acid (TCA) cycle for energy supply. During the process, the abnormal glutamine metabolism would ultimately lead to the pathological changes of pulmonary arterial hypertension via modulation of redox homeostasis, cell proliferation, autophagy and synthesis of biological macromolecules. Myc, MYC proto-oncogene; KRAS, kirsten rat sarcoma viral oncogene; p53, p53 gene; GLUD, glutamate dehydrogenase; ISO, isocitrate; Cit, citrate; OAA, oxaloacetate; Mal, malate; Fum, fumarase; Suc, succinic acid; Asn, asparagine; Asp, aspartate; ASL, argininosuccinate lyase; NO, nitric oxide; Pyr, pyruvate; NADPH, nicotinamide adenine dinucleotide phosphate; NADP, nicotinamide adenine dinucleotide phosphate.